Secor Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Secor Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-42,704	Closed	-$1.44M	–	552
2018 Q2	$1.44M	Buy	+42,704	New	+$1.33M	0.12%	251
2017 Q4	–	Sell	-23,722	Closed	-$475K	–	575
2017 Q3	$475K	Buy	+23,722	New	+$464K	0.05%	356
2015 Q4	–	Sell	-10,158	Closed	-$271K	–	618
2015 Q3	$271K	Buy	+10,158	New	+$434K	0.08%	377

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Secor Capital Advisors's PTCT Position: Q3 2018 in Review

Secor Capital Advisors sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 42,704 shares — an estimated $1.44M sold.

Secor Capital Advisors first reported a position in PTCT in Q3 2015 and held it in 3 quarters. The position peaked at $1.44M in Q2 2018. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

Secor Capital Advisors reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
Secor Capital Advisors sold 42,704 PTC Therapeutics shares in Q3 2018, an estimated $1.44M.
Secor Capital Advisors first reported a position in PTC Therapeutics in Q3 2015 and held it in 3 quarters.
Secor Capital Advisors's PTC Therapeutics position peaked at $1.44M in Q2 2018.
180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.